JPWO2022067039A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022067039A5 JPWO2022067039A5 JP2023519000A JP2023519000A JPWO2022067039A5 JP WO2022067039 A5 JPWO2022067039 A5 JP WO2022067039A5 JP 2023519000 A JP2023519000 A JP 2023519000A JP 2023519000 A JP2023519000 A JP 2023519000A JP WO2022067039 A5 JPWO2022067039 A5 JP WO2022067039A5
- Authority
- JP
- Japan
- Prior art keywords
- mitapivat
- composition
- pediatric subject
- amount
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940069680 mitapivat Drugs 0.000 claims description 189
- XAYGBKHKBBXDAK-UHFFFAOYSA-N n-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=CC=1C(=O)N(CC1)CCN1CC1CC1 XAYGBKHKBBXDAK-UHFFFAOYSA-N 0.000 claims description 189
- 150000003839 salts Chemical class 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 66
- 102000001554 Hemoglobins Human genes 0.000 claims description 38
- 108010054147 Hemoglobins Proteins 0.000 claims description 38
- 239000008187 granular material Substances 0.000 claims description 28
- 230000037396 body weight Effects 0.000 claims description 24
- 239000008185 minitablet Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims description 14
- 208000007056 sickle cell anemia Diseases 0.000 claims description 14
- 206010043395 Thalassaemia sickle cell Diseases 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 9
- DMRIPASJCJRBMV-UHFFFAOYSA-N N-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide sulfuric acid trihydrate Chemical compound O.O.O.OS(O)(=O)=O.O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1.O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1 DMRIPASJCJRBMV-UHFFFAOYSA-N 0.000 claims description 6
- 239000005414 inactive ingredient Substances 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- 230000009747 swallowing Effects 0.000 claims description 4
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- TXKRWVMEUQBFSO-UHFFFAOYSA-N sulfuric acid;trihydrate Chemical compound O.O.O.OS(O)(=O)=O TXKRWVMEUQBFSO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 73
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083834P | 2020-09-25 | 2020-09-25 | |
| US63/083,834 | 2020-09-25 | ||
| US202063107196P | 2020-10-29 | 2020-10-29 | |
| US63/107,196 | 2020-10-29 | ||
| US202163238483P | 2021-08-30 | 2021-08-30 | |
| US63/238,483 | 2021-08-30 | ||
| PCT/US2021/051957 WO2022067039A1 (en) | 2020-09-25 | 2021-09-24 | Pharmaceutical formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542701A JP2023542701A (ja) | 2023-10-11 |
| JP2023542701A5 JP2023542701A5 (https=) | 2024-10-01 |
| JPWO2022067039A5 true JPWO2022067039A5 (https=) | 2024-10-01 |
Family
ID=78179552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519000A Pending JP2023542701A (ja) | 2020-09-25 | 2021-09-24 | 薬学的製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230338283A1 (https=) |
| EP (1) | EP4216956A1 (https=) |
| JP (1) | JP2023542701A (https=) |
| KR (1) | KR20230074536A (https=) |
| AU (1) | AU2021347349A1 (https=) |
| CA (1) | CA3196829A1 (https=) |
| IL (1) | IL301596A (https=) |
| MX (1) | MX2023003431A (https=) |
| TW (1) | TW202228691A (https=) |
| WO (1) | WO2022067039A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2561132C2 (ru) | 2009-06-29 | 2015-08-20 | Аджиос Фармасьютикалз, Инк. | Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности |
| FI3307271T3 (fi) | 2015-06-11 | 2023-10-17 | Agios Pharmaceuticals Inc | Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä |
| JP7275130B2 (ja) * | 2017-11-22 | 2023-05-17 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態 |
-
2021
- 2021-09-24 EP EP21791565.1A patent/EP4216956A1/en active Pending
- 2021-09-24 KR KR1020237013787A patent/KR20230074536A/ko active Pending
- 2021-09-24 TW TW110135559A patent/TW202228691A/zh unknown
- 2021-09-24 US US18/028,058 patent/US20230338283A1/en active Pending
- 2021-09-24 MX MX2023003431A patent/MX2023003431A/es unknown
- 2021-09-24 JP JP2023519000A patent/JP2023542701A/ja active Pending
- 2021-09-24 AU AU2021347349A patent/AU2021347349A1/en active Pending
- 2021-09-24 CA CA3196829A patent/CA3196829A1/en active Pending
- 2021-09-24 WO PCT/US2021/051957 patent/WO2022067039A1/en not_active Ceased
- 2021-09-24 IL IL301596A patent/IL301596A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6558701B2 (en) | Multilayer tablet for administering a fixed combination of tramadol and diclofenac | |
| TW389696B (en) | Accelerated release composition containing bromocriptine | |
| KR101125462B1 (ko) | 모다피닐의 제약 제제 | |
| US9439866B2 (en) | Trazodone composition for once a day administration | |
| RU2540465C2 (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| JP2012136523A (ja) | テルビナフィンを含有する医薬組成物およびその使用 | |
| US7829120B2 (en) | Trazodone composition for once a day administration | |
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| CN114533689A (zh) | 延迟释放去铁酮片剂及其使用方法 | |
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| EP1863446A2 (en) | Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same | |
| US20240100011A1 (en) | Pediatric formulations of ferric citrate | |
| JPWO2022067039A5 (https=) | ||
| BR112020018925A2 (pt) | Composições não hormonais e métodos para contracepção masculina | |
| US20160263102A1 (en) | Pharmaceutical composition of bupropion and naltrexone | |
| WO2024155828A1 (en) | Uses of aminopyridines in the management of weight and satiety | |
| CN110913843A (zh) | 药物组合物 | |
| US20160220561A1 (en) | Pharmaceutical composition of bupropion and naltrexone | |
| US20240216284A1 (en) | Alpelisib formulation | |
| CN116801869A (zh) | 左旋多巴给药方案 | |
| JP2008273859A (ja) | 腎機能障害を持つ心不全患者を治療するためのコハク酸シベンゾリンを有効成分とする不整脈治療剤 | |
| AU2269495A (en) | Use of isosorbide-5-mononitrate | |
| HK40030435A (en) | Delayed release deferiprone tablets and methods of using the same | |
| BRPI0615577B1 (pt) | Composição farmacêutica de liberação prolongada e uso da mesma | |
| JPH047323B2 (https=) |